In patients without HIVLD, ABCG2 34AA genotype displayed a risk for dyslipidemia (13.3% vs. 13.3%, P = 0.44, OR = 3.24, 95% CI 0.37–23.98), and ABCG2 34GG and ABCG2 34GA genotypes were distributed almost similarly (60.0% vs. 67.6%; 26.7% vs. 27.8%) when compared between impaired cholesterol level and normal cholesterol level. Here, ABCG2 is linked to metabolic syndrome.